Presently, there are a multitude of options available to women to control their fertility, depending on changing needs over a lifetime, as well as their health and specific medical conditions. Temporary choices include barrier methods, e.g., the female and male condoms, oral contraceptives, and intrauterine devices. Permanent solutions include sterilization surgery for men or women and, more recently, noninvasive fallopian tube occlusion for women. The efficacy, risks, side effect profile, and cost for each form of contraception are important considerations for each woman. There are many choices for women to consider for contraception. In the United States alone, greater than 11 million women have chosen tubal sterilization as their contraceptive method of choice, with greater than 300,000 women choosing transcervical fallopian tube occlusion . While LTL is the gold standard, more patients will continue to opt for noninvasive techniques such as transcervical fallopian tube occlusion as a simple, safe, and effective solution.
Palmer SN, Greenberg JA. Transcervical sterilization: a comparison of Essure permanent birth control system and Adiana permanent contraception system. Rev Obstet Gynecol. 2009;2(2):84–92.PubMedGoogle Scholar
Kerin JF, Cooper JM, Price T, et al. Hysteroscopic sterilization using a micro-insert device: results of a multicentre Phase II study. Hum Reprod. 2003;18:1223–30.PubMedCrossRefGoogle Scholar
Essure physician training manual: HSG protocol. San Carlos, CA Conceptus, 2002.Google Scholar
McSwain H, Shaw C, Hall LD. Placement of the Essure permanent birth control device with fluoroscopic guidance: a novel method for tubal sterilization. J Vasc Interv Radiol. 2005;16(7):1007–12.PubMedGoogle Scholar
Weston G, Bowditch J. Office ultrasound should be the first-line investigation for confirmation of correct ESSURE placement. Aust N Z J Obstet Gynaecol. 2005;45(4):312–5.PubMedCrossRefGoogle Scholar
Teoh M, Meagher S, Kovacs G. Ultrasound detection of the Essure permanent birth control device: a case series. Aust N Z J Obstet Gynaecol. 2003;43(5):378–80.PubMedCrossRefGoogle Scholar
Veersema S, Vleugels MP, Timmermans A, Brölmann HA. Follow-up of successful bilateral placement of Essure microinserts with ultrasound. Fertil Steril. 2005;84(6):1733–6.PubMedCrossRefGoogle Scholar
Legendre G, Gervaise A, Levaillant JM, et al. Assessment of three-dimensional ultrasound examination classification to check the position of the tubal sterilization microinsert. Fertil Steril. 2010;94:2732–5.PubMedCrossRefGoogle Scholar
Cooper JM, Carignan CS, Cher D, Kerin JF. Microinsert nonincisional hysteroscopic sterilization. Obstet Gynecol. 2003;102:59–67.Google Scholar
Vancaillie TG, Anderson TL, Johns DA. A 12-month prospective evaluation of transcervical sterilization using implantable polymer matrices. Obstet Gynecol. 2008;112(6):1270–7.PubMedCrossRefGoogle Scholar
U.S. Food and Drug Administration, Centers for Devices and Radiological Health, Guidance for Industry - Uniform Contraceptive Labeling, July 23, 1998, http://www.fda.gov/cdrh/ode/contrlab.html, accessed on 09/05/2011.